Program
tizanidine
Also written as “Tizanidine”, “Zanaflex Capsules” and “tizanidine 8 mg”.
Its studies are mostly in Muscle Spasticity · Cognitive Dysfunction · Melanoma · Multiple Sclerosis · Cerebral Palsy, led by 4 companies.
Drug pageTizanidine: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Teva Pharmaceutical Industriesits history only | 30 open or running | phase 2since Jul 27, 2006 | Feb 2, 2006 | none ahead |
| Acorda Therapeuticsits history only | 20 open or running | phase 2since Apr 22, 2013 | Jul 25, 2011 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Feb 8, 2010 | Feb 8, 2010 | none ahead |
| Elan Pharmaceuticals | 10 open or running | phase 3since Oct 8, 2002 | Oct 8, 2002 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Elan Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 8, 2002First study: phase 3 study in Multiple SclerosisFirst studyNCT00047580 · 120 enrolled · United States
TargetBeta
“Adrenergic receptor alpha-2 agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| brimonidinerule | AbbVie | phase 4 | 54 |
| Dexmedetomidinerule | Pfizer | phase 4 | 46 |
| Oxymetazolinerule | AbbVie | phase 4 | 20 |
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
| Clonidinerule | pharmafina | phase 4 | 5 |
| lofexidinerule | uswm-llc-dba-us-worldmeds | phase 3 | 15 |
Studies
The one study Elan Pharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00047580Multiple Sclerosis · United States | 3 | Completed | 120 |
How it is read
Names in the registry
- “Tizanidine”, 4 entries
- “Zanaflex Capsules”, 4 entries
- “tizanidine 8 mg”, 1 entry
- “tizanidine 8mg”, 1 entry
- “tizanidine hydrochloride capsule”, 1 entry
Conditions, from the studies’ own filings
- Muscle Spasticity, 3 studies
- Cognitive Dysfunction, 1 study
- Melanoma, 1 study
- Multiple Sclerosis, 1 study
- Cerebral Palsy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.